相关实验视频
Updated: Jul 17, 2025

08:36
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
1.1K
阿布罗西提尼布用于治疗亚托邦性皮炎
Ana Maria Lé1, Melinda Gooderham2, Tiago Torres1,3
1Department of Dermatology, Centro Hospitalar Universitário do Porto, Porto, 4000-001, Portugal.
Immunotherapy
|September 5, 2023
概括
艾布罗西替尼 (abrocitinib) 是一种口服的JAK1抑制剂,有效治疗亚托皮炎,显示出更快的缓解和与dupilumab相比或更高的疗效. 它提供了有利的安全性,并具有可控的副作用.
科学领域:
- 皮肤病学 皮肤病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 亚托皮炎是一种慢性炎症性皮肤疾病.
- 细胞因子通路在亚托邦性皮肤炎的发病过程中起着至关重要的作用.
- 抑制JAK1是一种有针对性的治疗方法.
研究的目的:
- 评估abrocitinib在治疗阿托皮性皮肤炎中的疗效和安全性.
- 为了比较abrocitinib与dupilumab和安慰剂的有效性.
- 评估abrocitinib的不同剂量策略.
主要方法:
- 临床试验涉及阿托皮性皮肤炎患者.
- 服用口服阿布罗西替尼 (200毫克和100毫克) 和dupilumab.
- 评估疗效终点,包括皮肤清除和缓解.
- 对不良事件和实验室参数的监测.
主要成果:
- 阿布罗西替尼 (200毫克和100毫克) 的疗效与杜皮卢马布 (dupilumab) 相当,且优于安慰剂.
- 与dupilumab相比,abrocitinib 200 mg显示出更快的起作用和的缓解.
- 使用abrocitinib的诱导维护策略在超过55%的患者中预防了40周的发作.
- 常见的不良反应是不严重的,观察到与剂量相关的血小板计数下降,没有临床影响.
结论:
- 阿布罗西替尼 (abrocitinib) 是一种高度有效的口服治疗阿托皮性皮肤炎的药物.
- 该药物提供了有利的安全性和快速缓解症状.
- 阿布罗西提尼布为治疗亚托邦性皮肤炎提供了一种有价值的治疗选择.
更多相关视频
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
173
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
173
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
195
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
195
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
149
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
149
Inflammatory Bowel Disease IV: Pharmacological Management
152
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
152
Antiasthma Drugs: β2-Adrenoceptor Agonists
298
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
298
Drugs for Treatment of Ulcerative Colitis in IBD
173
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
173

